Human and animal studies have suggested that decreased adiponectin levels are an independent risk factor for cardiovascular diseases [48] and act as an emerging biomarker of non-alcoholic fatty liver disease [49]. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.